金吾财讯 | 荷兰全球免疫学创新巨头Argenx SE（ARGX）宣布，已通过其全资子公司Avena Merger Sub Inc.正式启动对临床阶段生物制药公司Forte Biosciences（FBRX）的现金要约收购。Argenx拟以每股77.00美元的现金价格收购Forte所有已发行及流通在外的普通股，要约收购自2026年8月6日正式开启，将于美东时间2026年8月26日到期。不过，该交易还需要获得代表Forte已发行股份超50%的有效预先要约与接纳，也须符合美国HSR法案的等待期届满或提前终止。根据公告，本次交易不设任何融资前提条件，要约完成后，双方将根据特拉华州通用公司法（DGCL）第251（h）条实施后续合并，无需再召开Forte股东大会投票，未参与要约的剩余股份将同样获得每股77.00美元的现金对价，合并后Forte将成为Argenx的全资子公司。据悉，Forte董事会已在提交给美国证券交易委员会（SEC）的Schedule 14D-9文件中，正式建议公司股东接受该要约并出让股份。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.